Loqir personal page - To The Moon

Loqir

Loqir

No personal profile

118Follow

0Followers

0Topic

0Badge

2021-06-07

A

3 Robinhood Stocks That Could Make You a Lot Richer Than AMC Will

2021-05-20

A

Sorry, the original content has been removed

2021-04-21

It depends

Will Regeneron's COVID Cocktail Win Be Short-Lived?

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3575628371697362","uuid":"3575628371697362","gmtCreate":1612536765782,"gmtModify":1619003089893,"name":"Loqir","pinyin":"loqir","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/976eabb1a57844062c23a691d65a6743","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":118,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.11.03","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.23","exceedPercentage":"60.43%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.93%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":114880381,"gmtCreate":1623065313343,"gmtModify":1704195306537,"author":{"id":"3575628371697362","authorId":"3575628371697362","name":"Loqir","avatar":"https://static.tigerbbs.com/976eabb1a57844062c23a691d65a6743","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575628371697362","authorIdStr":"3575628371697362"},"themes":[],"htmlText":"A","listText":"A","text":"A","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/114880381","repostId":"2141286115","repostType":4,"repost":{"id":"2141286115","kind":"highlight","pubTimestamp":1623052500,"share":"https://ttm.financial/m/news/2141286115?lang=&edition=fundamental","pubTime":"2021-06-07 15:55","market":"us","language":"en","title":"3 Robinhood Stocks That Could Make You a Lot Richer Than AMC Will","url":"https://stock-news.laohu8.com/highlight/detail?id=2141286115","media":"Motley Fool","summary":"The long-term prospects look much brighter for these great companies.","content":"<p>There's a good reason why <b>AMC Entertainment</b> ranks as the third most popular stock for Robinhood investors. Shares of the theater chain have skyrocketed more than 2,500% so far this year. Most of those gains have come over the last few weeks.</p><p>Investors are deluding themselves if they think that kind of momentum for AMC is sustainable. However, there are other popular Robinhood stocks that do have attractive growth prospects. Here are three Robinhood stocks that could make you a lot richer than AMC will going forward.</p><p><img src=\"https://static.tigerbbs.com/8615f62a24d693e4bc1bbaeadc93a39c\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h2><a href=\"https://laohu8.com/S/FB\">Facebook</a></h2><p>Don't believe for <a href=\"https://laohu8.com/S/AONE\">one</a> second that lots of people have thrown in the towel on&nbsp;<b>Facebook</b> (NASDAQ:FB). The social media giant's number of monthly active users has continued to climb, topping 2.85 billion in the first quarter of 2021. Meanwhile, the number of frequent moviegoers -- AMC's prime customers -- was slipping in 2019 before anyone had ever heard of COVID-19.</p><p>Facebook is working hard to build a trillion-dollar empire. One key component of this effort is to continue attracting users to its social media platforms so that it can sell more ads. However, the company isn't just focused on social media. CEO Mark Zuckerberg highlighted three areas in Facebook's Q1 update that could be massive growth drivers in the future -- augmented and virtual reality (AR/VR), commerce, and the \"creator economy.\"</p><p>The company is already a leader in VR with its Oculus devices. Facebook and Ray-Ban have first-generation AR smart glasses on the way. It's also developing new devices including haptic gloves plus a virtual world called Horizon. Zuckerberg thinks that AR and VR will \"unlock a massive amount of value\" over time.</p><p>As for e-commerce, more than 1 billion people already visit Facebook Marketplace each month. Facebook recently launched Shops, an online storefront platform that has more than 250 million monthly visitors. The company is also developing a platform and tools that support the creator economy, including options for content creators to monetize their offerings.</p><h2>Moderna</h2><p><b>Moderna</b> (NASDAQ:MRNA) stands as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the key reasons why AMC could see its fortunes improve in 2021. The COVID-19 vaccine developed by Moderna has been given to millions of Americans and remains one of only three vaccines to secure U.S. Emergency Use Authorization so far.</p><p>As of its Q1 update in early May, Moderna had advanced purchase agreements in place for its COVID-19 vaccine totaling more than $19 billion. Since then, the company has picked up additional supply deals.</p><p>Moderna seems likely to make even more money next year than it will in 2021. Beyond 2022, the company anticipates that emerging coronavirus variants will result in the need for annual vaccinations.</p><p>But is all of this growth already priced into the biotech stock? Nope. Moderna's shares currently trade at only nine times expected earnings. With plenty of other pipeline candidates based on its messenger RNA technology potentially on the way, Moderna could easily make investors who hold on for the long run much richer.</p><h2>Square</h2><p>Like AMC,&nbsp;<b>Square</b> (NYSE:SQ) should directly benefit from the reopening of the U.S. economy. The company's seller ecosystem serves many small and medium-sized businesses that were hurt by the COVID-19 pandemic.</p><p>Square will likely be in a position to offer these business customers even more value going forward. It plans to introduce business checking and savings accounts, according to a recent Bloomberg report. This move isn't surprising, as Square hasn't made a secret of its desire to transition into banking services.</p><p>The company's biggest growth driver, though, is its Cash App ecosystem. Cash App currently supports a wide range of features, including peer-to-peer payments, a credit card, and buying and selling stocks and <b>Bitcoin</b>.</p><p>Probably the biggest knock against Square is its valuation. The stock trades at more than 150 times expected earnings. That valuation is still more attractive than AMC's, though. More importantly, the shift to a cashless society seems unstoppable. Square's growth prospects for both its seller and Cash App ecosystems make a premium price worth paying.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Robinhood Stocks That Could Make You a Lot Richer Than AMC Will</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Robinhood Stocks That Could Make You a Lot Richer Than AMC Will\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 15:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/06/3-robinhood-stocks-that-could-make-you-a-lot-riche/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There's a good reason why AMC Entertainment ranks as the third most popular stock for Robinhood investors. Shares of the theater chain have skyrocketed more than 2,500% so far this year. Most of those...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/06/3-robinhood-stocks-that-could-make-you-a-lot-riche/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","SQ":"Block"},"source_url":"https://www.fool.com/investing/2021/06/06/3-robinhood-stocks-that-could-make-you-a-lot-riche/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2141286115","content_text":"There's a good reason why AMC Entertainment ranks as the third most popular stock for Robinhood investors. Shares of the theater chain have skyrocketed more than 2,500% so far this year. Most of those gains have come over the last few weeks.Investors are deluding themselves if they think that kind of momentum for AMC is sustainable. However, there are other popular Robinhood stocks that do have attractive growth prospects. Here are three Robinhood stocks that could make you a lot richer than AMC will going forward.Image source: Getty Images.FacebookDon't believe for one second that lots of people have thrown in the towel on Facebook (NASDAQ:FB). The social media giant's number of monthly active users has continued to climb, topping 2.85 billion in the first quarter of 2021. Meanwhile, the number of frequent moviegoers -- AMC's prime customers -- was slipping in 2019 before anyone had ever heard of COVID-19.Facebook is working hard to build a trillion-dollar empire. One key component of this effort is to continue attracting users to its social media platforms so that it can sell more ads. However, the company isn't just focused on social media. CEO Mark Zuckerberg highlighted three areas in Facebook's Q1 update that could be massive growth drivers in the future -- augmented and virtual reality (AR/VR), commerce, and the \"creator economy.\"The company is already a leader in VR with its Oculus devices. Facebook and Ray-Ban have first-generation AR smart glasses on the way. It's also developing new devices including haptic gloves plus a virtual world called Horizon. Zuckerberg thinks that AR and VR will \"unlock a massive amount of value\" over time.As for e-commerce, more than 1 billion people already visit Facebook Marketplace each month. Facebook recently launched Shops, an online storefront platform that has more than 250 million monthly visitors. The company is also developing a platform and tools that support the creator economy, including options for content creators to monetize their offerings.ModernaModerna (NASDAQ:MRNA) stands as one of the key reasons why AMC could see its fortunes improve in 2021. The COVID-19 vaccine developed by Moderna has been given to millions of Americans and remains one of only three vaccines to secure U.S. Emergency Use Authorization so far.As of its Q1 update in early May, Moderna had advanced purchase agreements in place for its COVID-19 vaccine totaling more than $19 billion. Since then, the company has picked up additional supply deals.Moderna seems likely to make even more money next year than it will in 2021. Beyond 2022, the company anticipates that emerging coronavirus variants will result in the need for annual vaccinations.But is all of this growth already priced into the biotech stock? Nope. Moderna's shares currently trade at only nine times expected earnings. With plenty of other pipeline candidates based on its messenger RNA technology potentially on the way, Moderna could easily make investors who hold on for the long run much richer.SquareLike AMC, Square (NYSE:SQ) should directly benefit from the reopening of the U.S. economy. The company's seller ecosystem serves many small and medium-sized businesses that were hurt by the COVID-19 pandemic.Square will likely be in a position to offer these business customers even more value going forward. It plans to introduce business checking and savings accounts, according to a recent Bloomberg report. This move isn't surprising, as Square hasn't made a secret of its desire to transition into banking services.The company's biggest growth driver, though, is its Cash App ecosystem. Cash App currently supports a wide range of features, including peer-to-peer payments, a credit card, and buying and selling stocks and Bitcoin.Probably the biggest knock against Square is its valuation. The stock trades at more than 150 times expected earnings. That valuation is still more attractive than AMC's, though. More importantly, the shift to a cashless society seems unstoppable. Square's growth prospects for both its seller and Cash App ecosystems make a premium price worth paying.","news_type":1},"isVote":1,"tweetType":1,"viewCount":521,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3582854091383813","authorId":"3582854091383813","name":"J7821717","avatar":"https://static.tigerbbs.com/af3e42db26d8c0bcd55e8b1c86a6f8ac","crmLevel":2,"crmLevelSwitch":0,"idStr":"3582854091383813","authorIdStr":"3582854091383813"},"content":"Like and comment","text":"Like and comment","html":"Like and comment"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":130855033,"gmtCreate":1621525558122,"gmtModify":1704359154811,"author":{"id":"3575628371697362","authorId":"3575628371697362","name":"Loqir","avatar":"https://static.tigerbbs.com/976eabb1a57844062c23a691d65a6743","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575628371697362","authorIdStr":"3575628371697362"},"themes":[],"htmlText":"A","listText":"A","text":"A","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/130855033","repostId":"1114639105","repostType":4,"isVote":1,"tweetType":1,"viewCount":420,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":378382981,"gmtCreate":1619001463443,"gmtModify":1704718105534,"author":{"id":"3575628371697362","authorId":"3575628371697362","name":"Loqir","avatar":"https://static.tigerbbs.com/976eabb1a57844062c23a691d65a6743","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575628371697362","authorIdStr":"3575628371697362"},"themes":[],"htmlText":"It depends&nbsp;","listText":"It depends&nbsp;","text":"It depends","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/378382981","repostId":"2129875413","repostType":4,"repost":{"id":"2129875413","kind":"highlight","pubTimestamp":1619001180,"share":"https://ttm.financial/m/news/2129875413?lang=&edition=fundamental","pubTime":"2021-04-21 18:33","market":"us","language":"en","title":"Will Regeneron's COVID Cocktail Win Be Short-Lived?","url":"https://stock-news.laohu8.com/highlight/detail?id=2129875413","media":"Motley Fool","summary":"The biotech's antibody therapy continues to show promise. But there's considerable uncertainty about its long-term prospects.","content":"<p><b><a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a></b> (NASDAQ:REGN) recently racked up a couple of additional successes with late-stage studies of its COVID-19 antibody cocktail REGEN-COV.&nbsp;In this <i>Motley Fool Live</i> video <b>recorded on April 14, 2021</b>, Motley Fool contributors Keith Speights and Brian Orelli discuss whether the biotech's COVID cocktail win will only be short-lived.</p><p><b>Keith Speights:</b> Regeneron Pharmaceuticals, the ticker there is REGN, had two positive announcements for its COVID-19 antibody cocktail, REGEN-COV. They announced both of these new developments on Monday.</p><p>The company reported results from a late-stage study that showed that this antibody cocktail significantly reduced progression to symptomatic COVID-19 in patients who had been recently infected. It also announced results from another phase 3 study that showed the antibody cocktail reduced the risk of infection for individuals in households where another person had been infected by the coronavirus.</p><p>These are definitely positive stories for Regeneron, but do you think these wins will translate to significant revenue for the biotech? Or could these wins actually be short-lived?</p><p><b>Brian Orelli:</b> Obviously as more and more people get vaccinated the infection rates should go down, and then therefore the opportunity to treat people either prophylactically because they've been exposed or because they realized that they test positive but don't have any symptoms and then want this antibody cocktail, that opportunity is going to be go down, but it's not going to go to zero, and so I think there's an opportunity for some treatments.</p><p>But certainly the market for treatments is going to diminish substantially over the next few months and into the next year. I don't know.</p><p>The other wildcard here is the variance. The variance pop up and we can't keep up fast enough with them, and they are infecting enough people that are already vaccinated and we can't keep up creating new vaccine fast enough, then I think that's another opportunity for the treatments that they don't have right now.</p><p><b>Speights:</b> I think that's a really good take on it, Brian. If you're looking at potentially investing in Regeneron, there are other reasons to consider buying the stock. I think you said recently, Brian, that they just don't fail. [laughs] Has Regeneron had any failures? [laughs] Not recently.</p><p><b>Orelli:</b> Not late-stage failure certainly. I can't think of any failures that they've had.</p><p><b>Speights:</b> The company has several drugs with fast-growing sales. This is obviously promising news with this antibody therapy. But like you say, Brian, it remains to be seen whether or not it's going to have market traction over the long run. It's hard to say. It's hard to say what's going to happen in the world of COVID-19 beyond the pandemic.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Will Regeneron's COVID Cocktail Win Be Short-Lived?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWill Regeneron's COVID Cocktail Win Be Short-Lived?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-21 18:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/21/will-regenerons-covid-cocktail-win-be-short-lived/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Regeneron Pharmaceuticals (NASDAQ:REGN) recently racked up a couple of additional successes with late-stage studies of its COVID-19 antibody cocktail REGEN-COV. In this Motley Fool Live video recorded...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/21/will-regenerons-covid-cocktail-win-be-short-lived/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司"},"source_url":"https://www.fool.com/investing/2021/04/21/will-regenerons-covid-cocktail-win-be-short-lived/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2129875413","content_text":"Regeneron Pharmaceuticals (NASDAQ:REGN) recently racked up a couple of additional successes with late-stage studies of its COVID-19 antibody cocktail REGEN-COV. In this Motley Fool Live video recorded on April 14, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether the biotech's COVID cocktail win will only be short-lived.Keith Speights: Regeneron Pharmaceuticals, the ticker there is REGN, had two positive announcements for its COVID-19 antibody cocktail, REGEN-COV. They announced both of these new developments on Monday.The company reported results from a late-stage study that showed that this antibody cocktail significantly reduced progression to symptomatic COVID-19 in patients who had been recently infected. It also announced results from another phase 3 study that showed the antibody cocktail reduced the risk of infection for individuals in households where another person had been infected by the coronavirus.These are definitely positive stories for Regeneron, but do you think these wins will translate to significant revenue for the biotech? Or could these wins actually be short-lived?Brian Orelli: Obviously as more and more people get vaccinated the infection rates should go down, and then therefore the opportunity to treat people either prophylactically because they've been exposed or because they realized that they test positive but don't have any symptoms and then want this antibody cocktail, that opportunity is going to be go down, but it's not going to go to zero, and so I think there's an opportunity for some treatments.But certainly the market for treatments is going to diminish substantially over the next few months and into the next year. I don't know.The other wildcard here is the variance. The variance pop up and we can't keep up fast enough with them, and they are infecting enough people that are already vaccinated and we can't keep up creating new vaccine fast enough, then I think that's another opportunity for the treatments that they don't have right now.Speights: I think that's a really good take on it, Brian. If you're looking at potentially investing in Regeneron, there are other reasons to consider buying the stock. I think you said recently, Brian, that they just don't fail. [laughs] Has Regeneron had any failures? [laughs] Not recently.Orelli: Not late-stage failure certainly. I can't think of any failures that they've had.Speights: The company has several drugs with fast-growing sales. This is obviously promising news with this antibody therapy. But like you say, Brian, it remains to be seen whether or not it's going to have market traction over the long run. It's hard to say. It's hard to say what's going to happen in the world of COVID-19 beyond the pandemic.","news_type":1},"isVote":1,"tweetType":1,"viewCount":486,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":114880381,"gmtCreate":1623065313343,"gmtModify":1704195306537,"author":{"id":"3575628371697362","authorId":"3575628371697362","name":"Loqir","avatar":"https://static.tigerbbs.com/976eabb1a57844062c23a691d65a6743","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575628371697362","authorIdStr":"3575628371697362"},"themes":[],"htmlText":"A","listText":"A","text":"A","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/114880381","repostId":"2141286115","repostType":4,"repost":{"id":"2141286115","kind":"highlight","pubTimestamp":1623052500,"share":"https://ttm.financial/m/news/2141286115?lang=&edition=fundamental","pubTime":"2021-06-07 15:55","market":"us","language":"en","title":"3 Robinhood Stocks That Could Make You a Lot Richer Than AMC Will","url":"https://stock-news.laohu8.com/highlight/detail?id=2141286115","media":"Motley Fool","summary":"The long-term prospects look much brighter for these great companies.","content":"<p>There's a good reason why <b>AMC Entertainment</b> ranks as the third most popular stock for Robinhood investors. Shares of the theater chain have skyrocketed more than 2,500% so far this year. Most of those gains have come over the last few weeks.</p><p>Investors are deluding themselves if they think that kind of momentum for AMC is sustainable. However, there are other popular Robinhood stocks that do have attractive growth prospects. Here are three Robinhood stocks that could make you a lot richer than AMC will going forward.</p><p><img src=\"https://static.tigerbbs.com/8615f62a24d693e4bc1bbaeadc93a39c\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p>Image source: Getty Images.</p><h2><a href=\"https://laohu8.com/S/FB\">Facebook</a></h2><p>Don't believe for <a href=\"https://laohu8.com/S/AONE\">one</a> second that lots of people have thrown in the towel on&nbsp;<b>Facebook</b> (NASDAQ:FB). The social media giant's number of monthly active users has continued to climb, topping 2.85 billion in the first quarter of 2021. Meanwhile, the number of frequent moviegoers -- AMC's prime customers -- was slipping in 2019 before anyone had ever heard of COVID-19.</p><p>Facebook is working hard to build a trillion-dollar empire. One key component of this effort is to continue attracting users to its social media platforms so that it can sell more ads. However, the company isn't just focused on social media. CEO Mark Zuckerberg highlighted three areas in Facebook's Q1 update that could be massive growth drivers in the future -- augmented and virtual reality (AR/VR), commerce, and the \"creator economy.\"</p><p>The company is already a leader in VR with its Oculus devices. Facebook and Ray-Ban have first-generation AR smart glasses on the way. It's also developing new devices including haptic gloves plus a virtual world called Horizon. Zuckerberg thinks that AR and VR will \"unlock a massive amount of value\" over time.</p><p>As for e-commerce, more than 1 billion people already visit Facebook Marketplace each month. Facebook recently launched Shops, an online storefront platform that has more than 250 million monthly visitors. The company is also developing a platform and tools that support the creator economy, including options for content creators to monetize their offerings.</p><h2>Moderna</h2><p><b>Moderna</b> (NASDAQ:MRNA) stands as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the key reasons why AMC could see its fortunes improve in 2021. The COVID-19 vaccine developed by Moderna has been given to millions of Americans and remains one of only three vaccines to secure U.S. Emergency Use Authorization so far.</p><p>As of its Q1 update in early May, Moderna had advanced purchase agreements in place for its COVID-19 vaccine totaling more than $19 billion. Since then, the company has picked up additional supply deals.</p><p>Moderna seems likely to make even more money next year than it will in 2021. Beyond 2022, the company anticipates that emerging coronavirus variants will result in the need for annual vaccinations.</p><p>But is all of this growth already priced into the biotech stock? Nope. Moderna's shares currently trade at only nine times expected earnings. With plenty of other pipeline candidates based on its messenger RNA technology potentially on the way, Moderna could easily make investors who hold on for the long run much richer.</p><h2>Square</h2><p>Like AMC,&nbsp;<b>Square</b> (NYSE:SQ) should directly benefit from the reopening of the U.S. economy. The company's seller ecosystem serves many small and medium-sized businesses that were hurt by the COVID-19 pandemic.</p><p>Square will likely be in a position to offer these business customers even more value going forward. It plans to introduce business checking and savings accounts, according to a recent Bloomberg report. This move isn't surprising, as Square hasn't made a secret of its desire to transition into banking services.</p><p>The company's biggest growth driver, though, is its Cash App ecosystem. Cash App currently supports a wide range of features, including peer-to-peer payments, a credit card, and buying and selling stocks and <b>Bitcoin</b>.</p><p>Probably the biggest knock against Square is its valuation. The stock trades at more than 150 times expected earnings. That valuation is still more attractive than AMC's, though. More importantly, the shift to a cashless society seems unstoppable. Square's growth prospects for both its seller and Cash App ecosystems make a premium price worth paying.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Robinhood Stocks That Could Make You a Lot Richer Than AMC Will</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Robinhood Stocks That Could Make You a Lot Richer Than AMC Will\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-07 15:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/06/3-robinhood-stocks-that-could-make-you-a-lot-riche/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There's a good reason why AMC Entertainment ranks as the third most popular stock for Robinhood investors. Shares of the theater chain have skyrocketed more than 2,500% so far this year. Most of those...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/06/3-robinhood-stocks-that-could-make-you-a-lot-riche/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","SQ":"Block"},"source_url":"https://www.fool.com/investing/2021/06/06/3-robinhood-stocks-that-could-make-you-a-lot-riche/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2141286115","content_text":"There's a good reason why AMC Entertainment ranks as the third most popular stock for Robinhood investors. Shares of the theater chain have skyrocketed more than 2,500% so far this year. Most of those gains have come over the last few weeks.Investors are deluding themselves if they think that kind of momentum for AMC is sustainable. However, there are other popular Robinhood stocks that do have attractive growth prospects. Here are three Robinhood stocks that could make you a lot richer than AMC will going forward.Image source: Getty Images.FacebookDon't believe for one second that lots of people have thrown in the towel on Facebook (NASDAQ:FB). The social media giant's number of monthly active users has continued to climb, topping 2.85 billion in the first quarter of 2021. Meanwhile, the number of frequent moviegoers -- AMC's prime customers -- was slipping in 2019 before anyone had ever heard of COVID-19.Facebook is working hard to build a trillion-dollar empire. One key component of this effort is to continue attracting users to its social media platforms so that it can sell more ads. However, the company isn't just focused on social media. CEO Mark Zuckerberg highlighted three areas in Facebook's Q1 update that could be massive growth drivers in the future -- augmented and virtual reality (AR/VR), commerce, and the \"creator economy.\"The company is already a leader in VR with its Oculus devices. Facebook and Ray-Ban have first-generation AR smart glasses on the way. It's also developing new devices including haptic gloves plus a virtual world called Horizon. Zuckerberg thinks that AR and VR will \"unlock a massive amount of value\" over time.As for e-commerce, more than 1 billion people already visit Facebook Marketplace each month. Facebook recently launched Shops, an online storefront platform that has more than 250 million monthly visitors. The company is also developing a platform and tools that support the creator economy, including options for content creators to monetize their offerings.ModernaModerna (NASDAQ:MRNA) stands as one of the key reasons why AMC could see its fortunes improve in 2021. The COVID-19 vaccine developed by Moderna has been given to millions of Americans and remains one of only three vaccines to secure U.S. Emergency Use Authorization so far.As of its Q1 update in early May, Moderna had advanced purchase agreements in place for its COVID-19 vaccine totaling more than $19 billion. Since then, the company has picked up additional supply deals.Moderna seems likely to make even more money next year than it will in 2021. Beyond 2022, the company anticipates that emerging coronavirus variants will result in the need for annual vaccinations.But is all of this growth already priced into the biotech stock? Nope. Moderna's shares currently trade at only nine times expected earnings. With plenty of other pipeline candidates based on its messenger RNA technology potentially on the way, Moderna could easily make investors who hold on for the long run much richer.SquareLike AMC, Square (NYSE:SQ) should directly benefit from the reopening of the U.S. economy. The company's seller ecosystem serves many small and medium-sized businesses that were hurt by the COVID-19 pandemic.Square will likely be in a position to offer these business customers even more value going forward. It plans to introduce business checking and savings accounts, according to a recent Bloomberg report. This move isn't surprising, as Square hasn't made a secret of its desire to transition into banking services.The company's biggest growth driver, though, is its Cash App ecosystem. Cash App currently supports a wide range of features, including peer-to-peer payments, a credit card, and buying and selling stocks and Bitcoin.Probably the biggest knock against Square is its valuation. The stock trades at more than 150 times expected earnings. That valuation is still more attractive than AMC's, though. More importantly, the shift to a cashless society seems unstoppable. Square's growth prospects for both its seller and Cash App ecosystems make a premium price worth paying.","news_type":1},"isVote":1,"tweetType":1,"viewCount":521,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3582854091383813","authorId":"3582854091383813","name":"J7821717","avatar":"https://static.tigerbbs.com/af3e42db26d8c0bcd55e8b1c86a6f8ac","crmLevel":2,"crmLevelSwitch":0,"idStr":"3582854091383813","authorIdStr":"3582854091383813"},"content":"Like and comment","text":"Like and comment","html":"Like and comment"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":130855033,"gmtCreate":1621525558122,"gmtModify":1704359154811,"author":{"id":"3575628371697362","authorId":"3575628371697362","name":"Loqir","avatar":"https://static.tigerbbs.com/976eabb1a57844062c23a691d65a6743","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575628371697362","authorIdStr":"3575628371697362"},"themes":[],"htmlText":"A","listText":"A","text":"A","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/130855033","repostId":"1114639105","repostType":4,"repost":{"id":"1114639105","kind":"news","pubTimestamp":1621524985,"share":"https://ttm.financial/m/news/1114639105?lang=&edition=fundamental","pubTime":"2021-05-20 23:36","market":"us","language":"en","title":"Today's Tech Sell-Off: Where to Invest $5,000 for the Next 5 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=1114639105","media":"Motley Fool","summary":"These tech giants might multiply your $5,000 investment substantially in the coming years.The Nasdaq-100 Technology Sector index has retreated more than 7% in the past month, bringing down the valuations of some fast-growing names in tech that were considered overvalued earlier. But one shouldn't forget that this same index has jumped more than 240% in the past five years, which means that a $5,000 investment in the index would be worth $17,000 now.Advanced Micro Devices  stock has done even bet","content":"<p>These tech giants might multiply your $5,000 investment substantially in the coming years.</p>\n<p>The&nbsp;<b>Nasdaq-100 Technology Sector</b>&nbsp;index has retreated more than 7% in the past month, bringing down the valuations of some fast-growing names in tech that were considered overvalued earlier. But one shouldn't forget that this same index has jumped more than 240% in the past five years, which means that a $5,000 investment in the index would be worth $17,000 now.</p>\n<p><b>Advanced Micro Devices</b>&nbsp;(NASDAQ:AMD)&nbsp;stock has done even better over five years, rising over 1,850% and turning $5,000 into nearly $100,000. Rival graphics card specialist&nbsp;<b>NVIDIA</b>(NASDAQ:NVDA)has soared over 1,200% over a similar period. Both stocks have pulled back thanks to the tech sell-off, but these two stocks could deliver outsized gains over the next five years as well, thanks to the catalysts they are sitting on. Let's find out why.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/45c65cfc8b2918e175d465448db6ae7c\" tg-width=\"2000\" tg-height=\"1427\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p><b>1. Advanced Micro Devices</b></p>\n<p>AMD's fortunes have&nbsp;changed big time&nbsp;over the past five years. A competitive product lineup has allowed it to&nbsp;take market share away&nbsp;from&nbsp;<b>Intel</b>&nbsp;(NASDAQ:INTC)&nbsp;in the x86 processor market, a trend that's expected to continue in the next five years.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c49fb00a03d9fc043669c6253b537fc8\" tg-width=\"720\" tg-height=\"387\"><span>AMD DATA BY YCHARTS</span></p>\n<p>AMD has made solid progress in the PC market through its Ryzen CPUs (central processing units) and Radeon GPUs (graphics processing units). According to the latest data&nbsp;from Steam Hardware Survey for April, AMD now controls almost 29.5% of the PC CPU space. It controlled 25% of the market in December 2020, with Intel holding the rest. Steam data is a credible source for PC market share information, as the platform is used by 120 million monthly active users worldwide.</p>\n<p>Meanwhile, Mercury Research estimates that AMD's desktop PC market share increased to 19.3% at the end of the first quarter, up from just 11.4% four years ago. It also holds 18% of the mobile CPU market. AMD's CPU market share is expected to&nbsp;jump as high as 50%&nbsp;in 2021 as per Wall Street. This doesn't seem surprising given thetechnology advantage&nbsp;AMD enjoys over Intel, as well as&nbsp;Chipzilla's troubles&nbsp;with getting its latest chips out of the gate.</p>\n<p>AMD has also turned on the heat in the laptop market. The company's Ryzen 5000 mobile processors are expected to&nbsp;power 50% more models&nbsp;this year and pave the way for more market share gains.</p>\n<p>Meanwhile, AMD has made solid progress in the server processor market, finishing Q1 with an 8.9% share. It was nowhere to be seen in server processors four years ago, but the&nbsp;arrival of the EPYC chips&nbsp;has given it a big shot in the arm. AMD is poised to&nbsp;take away more market share&nbsp;from Intel in servers in the coming years and could make billions of dollars from this space.</p>\n<p>On the other hand, the arrival of the latest gaming consoles from&nbsp;<b>Sony</b>&nbsp;and&nbsp;<b>Microsoft</b>&nbsp;that are powered by AMD's chips is&nbsp;moving the needle in a big way&nbsp;for the chipmaker. The PlayStation 5 has sold 7.8 million units so far. It is expected&nbsp;to sell over 200 million units over its lifetime, according to an analyst at Japanese firm Rakuten Securities, as compared to 116 million units of the previous generation PS4.</p>\n<p>What's more, AMD is reportedly getting&nbsp;80% more revenue from each unit of the PS5 over the PS4. So, a combination of higher shipments and stronger revenue from each gaming console should unlock a massive revenue opportunity for the company in the long run. Not surprisingly, analysts expect&nbsp;AMD to deliver almost 30% annual earnings growth over the next five years -- making it a&nbsp;top growth stock&nbsp;where one can park $5,000 right now, given that it is trading at less than 28 times&nbsp;forward earnings.</p>\n<p><b>2. NVIDIA</b></p>\n<p>NVIDIA has come a long way in the past five years. The chipmaker has&nbsp;branched out into&nbsp;several fast-growing applications such as data centers, artificial intelligence, autonomous cars, and&nbsp;5G wireless networks&nbsp;from supplying graphics cards for gaming PCs.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/60ad2c7070e39d4c3cca24654ff15c3d\" tg-width=\"720\" tg-height=\"387\"><span>NVDA DATA BY YCHARTS</span></p>\n<p>Gaming continues to be NVIDIA's biggest source of revenue, accounting for 46% of its top line last fiscal year. The segment's revenue was up 41% in fiscal 2021 to $7.7 billion, thanks to the launch of NVIDIA's new RTX 30 series graphics cards, which have set the sales charts on fire by triggering a&nbsp;massive upgrade cycle.</p>\n<p>NVIDIA estimates that 85% of its installed base is yet to upgrade to the RTX series cards, which pack a&nbsp;huge performance bump&nbsp;at aggressive price points over prior generation cards. That's a huge opportunity, as NVIDIA's installed base of gaming graphics cards&nbsp;stands at 140 million. More importantly, the company's new GPUs are driving an increase in the average selling price (ASP).</p>\n<p>The latest Ampere-based GPUs recorded&nbsp;an ASP of $360 in the first six months of their launch thanks to an increase in the proportion of customers buying higher-priced cards. That's 20% higher than the previous generation Turing cards that had an ASP of $300 in the initial six months, and well above the $245 ASP of the Pascal cards that were released&nbsp;five years ago.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/248662e56d72ba00757a9c18076ebd6b\" tg-width=\"2000\" tg-height=\"1125\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p>So, NVIDIA's gaming business could keep growing at a terrific pace over the next five years thanks to a combination of strong volumes and improved pricing. Jon Peddie Research estimates&nbsp;that 41.5 million discrete GPUs were sold in 2020, and NVIDIA&nbsp;dominated this market&nbsp;with a share of 82% at the end of the year. This bodes well for NVIDIA's future, as the GPU market is expected to clock annual growth of nearly 34% through 2027 as per third-party&nbsp;estimates.</p>\n<p>Beyond gaming, NVIDIA is sitting on huge opportunities in nascent markets such as self-driving cars. The company has struck several partnerships in this space and has already lined up automotive design wins&nbsp;worth $8 billion&nbsp;for the next five years. This figure could keep growing thanks to NVIDIA's solid product roadmap, which indicates that it is working on more powerful self-driving platforms that should hit the market in the coming years.</p>\n<p>Throw in the fact that NVIDIA's terrific growth in the data center market won't be fading any time soon, and investors will have one more reason to hold on to this tech titan. The data center business generated $6.7 billion in revenue in FY21, up 124% year over year. It accounted for 40% of the total revenue. NVIDIA is now branching out into new areas to ensure that this business keeps growing at elevated rates.</p>\n<p>It recently announced&nbsp;the Grace CPU, a server processor that's expected to go on sale in 2023. This would be new territory for NVIDIA, and success here could supercharge the company's data center business, as the server processor market is expected to be worth $19 billion&nbsp;by 2023.</p>\n<p>So, NVIDIA still has a lot of room for growth. Analysts forecast 20%-plus annual earnings growth for the next five years, though NVIDIA could do better if the new opportunities it is attacking bear fruit. In all, NVIDIA looks like a top stock where investors can park $5,000, as it is set for multi-year growth and trades at an attractive 36 times&nbsp;forward earnings as compared to 2020's average multiple of 46.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Today's Tech Sell-Off: Where to Invest $5,000 for the Next 5 Years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToday's Tech Sell-Off: Where to Invest $5,000 for the Next 5 Years\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-20 23:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/20/tech-sell-off-where-invest-5000-for-next-5-years/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>These tech giants might multiply your $5,000 investment substantially in the coming years.\nThe Nasdaq-100 Technology Sector index has retreated more than 7% in the past month, bringing down the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/20/tech-sell-off-where-invest-5000-for-next-5-years/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMD":"美国超微公司","NDX":"纳斯达克100指数","NVDA":"英伟达"},"source_url":"https://www.fool.com/investing/2021/05/20/tech-sell-off-where-invest-5000-for-next-5-years/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114639105","content_text":"These tech giants might multiply your $5,000 investment substantially in the coming years.\nThe Nasdaq-100 Technology Sector index has retreated more than 7% in the past month, bringing down the valuations of some fast-growing names in tech that were considered overvalued earlier. But one shouldn't forget that this same index has jumped more than 240% in the past five years, which means that a $5,000 investment in the index would be worth $17,000 now.\nAdvanced Micro Devices (NASDAQ:AMD) stock has done even better over five years, rising over 1,850% and turning $5,000 into nearly $100,000. Rival graphics card specialist NVIDIA(NASDAQ:NVDA)has soared over 1,200% over a similar period. Both stocks have pulled back thanks to the tech sell-off, but these two stocks could deliver outsized gains over the next five years as well, thanks to the catalysts they are sitting on. Let's find out why.\nIMAGE SOURCE: GETTY IMAGES.\n1. Advanced Micro Devices\nAMD's fortunes have changed big time over the past five years. A competitive product lineup has allowed it to take market share away from Intel (NASDAQ:INTC) in the x86 processor market, a trend that's expected to continue in the next five years.\nAMD DATA BY YCHARTS\nAMD has made solid progress in the PC market through its Ryzen CPUs (central processing units) and Radeon GPUs (graphics processing units). According to the latest data from Steam Hardware Survey for April, AMD now controls almost 29.5% of the PC CPU space. It controlled 25% of the market in December 2020, with Intel holding the rest. Steam data is a credible source for PC market share information, as the platform is used by 120 million monthly active users worldwide.\nMeanwhile, Mercury Research estimates that AMD's desktop PC market share increased to 19.3% at the end of the first quarter, up from just 11.4% four years ago. It also holds 18% of the mobile CPU market. AMD's CPU market share is expected to jump as high as 50% in 2021 as per Wall Street. This doesn't seem surprising given thetechnology advantage AMD enjoys over Intel, as well as Chipzilla's troubles with getting its latest chips out of the gate.\nAMD has also turned on the heat in the laptop market. The company's Ryzen 5000 mobile processors are expected to power 50% more models this year and pave the way for more market share gains.\nMeanwhile, AMD has made solid progress in the server processor market, finishing Q1 with an 8.9% share. It was nowhere to be seen in server processors four years ago, but the arrival of the EPYC chips has given it a big shot in the arm. AMD is poised to take away more market share from Intel in servers in the coming years and could make billions of dollars from this space.\nOn the other hand, the arrival of the latest gaming consoles from Sony and Microsoft that are powered by AMD's chips is moving the needle in a big way for the chipmaker. The PlayStation 5 has sold 7.8 million units so far. It is expected to sell over 200 million units over its lifetime, according to an analyst at Japanese firm Rakuten Securities, as compared to 116 million units of the previous generation PS4.\nWhat's more, AMD is reportedly getting 80% more revenue from each unit of the PS5 over the PS4. So, a combination of higher shipments and stronger revenue from each gaming console should unlock a massive revenue opportunity for the company in the long run. Not surprisingly, analysts expect AMD to deliver almost 30% annual earnings growth over the next five years -- making it a top growth stock where one can park $5,000 right now, given that it is trading at less than 28 times forward earnings.\n2. NVIDIA\nNVIDIA has come a long way in the past five years. The chipmaker has branched out into several fast-growing applications such as data centers, artificial intelligence, autonomous cars, and 5G wireless networks from supplying graphics cards for gaming PCs.\nNVDA DATA BY YCHARTS\nGaming continues to be NVIDIA's biggest source of revenue, accounting for 46% of its top line last fiscal year. The segment's revenue was up 41% in fiscal 2021 to $7.7 billion, thanks to the launch of NVIDIA's new RTX 30 series graphics cards, which have set the sales charts on fire by triggering a massive upgrade cycle.\nNVIDIA estimates that 85% of its installed base is yet to upgrade to the RTX series cards, which pack a huge performance bump at aggressive price points over prior generation cards. That's a huge opportunity, as NVIDIA's installed base of gaming graphics cards stands at 140 million. More importantly, the company's new GPUs are driving an increase in the average selling price (ASP).\nThe latest Ampere-based GPUs recorded an ASP of $360 in the first six months of their launch thanks to an increase in the proportion of customers buying higher-priced cards. That's 20% higher than the previous generation Turing cards that had an ASP of $300 in the initial six months, and well above the $245 ASP of the Pascal cards that were released five years ago.\nIMAGE SOURCE: GETTY IMAGES.\nSo, NVIDIA's gaming business could keep growing at a terrific pace over the next five years thanks to a combination of strong volumes and improved pricing. Jon Peddie Research estimates that 41.5 million discrete GPUs were sold in 2020, and NVIDIA dominated this market with a share of 82% at the end of the year. This bodes well for NVIDIA's future, as the GPU market is expected to clock annual growth of nearly 34% through 2027 as per third-party estimates.\nBeyond gaming, NVIDIA is sitting on huge opportunities in nascent markets such as self-driving cars. The company has struck several partnerships in this space and has already lined up automotive design wins worth $8 billion for the next five years. This figure could keep growing thanks to NVIDIA's solid product roadmap, which indicates that it is working on more powerful self-driving platforms that should hit the market in the coming years.\nThrow in the fact that NVIDIA's terrific growth in the data center market won't be fading any time soon, and investors will have one more reason to hold on to this tech titan. The data center business generated $6.7 billion in revenue in FY21, up 124% year over year. It accounted for 40% of the total revenue. NVIDIA is now branching out into new areas to ensure that this business keeps growing at elevated rates.\nIt recently announced the Grace CPU, a server processor that's expected to go on sale in 2023. This would be new territory for NVIDIA, and success here could supercharge the company's data center business, as the server processor market is expected to be worth $19 billion by 2023.\nSo, NVIDIA still has a lot of room for growth. Analysts forecast 20%-plus annual earnings growth for the next five years, though NVIDIA could do better if the new opportunities it is attacking bear fruit. In all, NVIDIA looks like a top stock where investors can park $5,000, as it is set for multi-year growth and trades at an attractive 36 times forward earnings as compared to 2020's average multiple of 46.","news_type":1},"isVote":1,"tweetType":1,"viewCount":420,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":378382981,"gmtCreate":1619001463443,"gmtModify":1704718105534,"author":{"id":"3575628371697362","authorId":"3575628371697362","name":"Loqir","avatar":"https://static.tigerbbs.com/976eabb1a57844062c23a691d65a6743","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575628371697362","authorIdStr":"3575628371697362"},"themes":[],"htmlText":"It depends&nbsp;","listText":"It depends&nbsp;","text":"It depends","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/378382981","repostId":"2129875413","repostType":4,"repost":{"id":"2129875413","kind":"highlight","pubTimestamp":1619001180,"share":"https://ttm.financial/m/news/2129875413?lang=&edition=fundamental","pubTime":"2021-04-21 18:33","market":"us","language":"en","title":"Will Regeneron's COVID Cocktail Win Be Short-Lived?","url":"https://stock-news.laohu8.com/highlight/detail?id=2129875413","media":"Motley Fool","summary":"The biotech's antibody therapy continues to show promise. But there's considerable uncertainty about its long-term prospects.","content":"<p><b><a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a></b> (NASDAQ:REGN) recently racked up a couple of additional successes with late-stage studies of its COVID-19 antibody cocktail REGEN-COV.&nbsp;In this <i>Motley Fool Live</i> video <b>recorded on April 14, 2021</b>, Motley Fool contributors Keith Speights and Brian Orelli discuss whether the biotech's COVID cocktail win will only be short-lived.</p><p><b>Keith Speights:</b> Regeneron Pharmaceuticals, the ticker there is REGN, had two positive announcements for its COVID-19 antibody cocktail, REGEN-COV. They announced both of these new developments on Monday.</p><p>The company reported results from a late-stage study that showed that this antibody cocktail significantly reduced progression to symptomatic COVID-19 in patients who had been recently infected. It also announced results from another phase 3 study that showed the antibody cocktail reduced the risk of infection for individuals in households where another person had been infected by the coronavirus.</p><p>These are definitely positive stories for Regeneron, but do you think these wins will translate to significant revenue for the biotech? Or could these wins actually be short-lived?</p><p><b>Brian Orelli:</b> Obviously as more and more people get vaccinated the infection rates should go down, and then therefore the opportunity to treat people either prophylactically because they've been exposed or because they realized that they test positive but don't have any symptoms and then want this antibody cocktail, that opportunity is going to be go down, but it's not going to go to zero, and so I think there's an opportunity for some treatments.</p><p>But certainly the market for treatments is going to diminish substantially over the next few months and into the next year. I don't know.</p><p>The other wildcard here is the variance. The variance pop up and we can't keep up fast enough with them, and they are infecting enough people that are already vaccinated and we can't keep up creating new vaccine fast enough, then I think that's another opportunity for the treatments that they don't have right now.</p><p><b>Speights:</b> I think that's a really good take on it, Brian. If you're looking at potentially investing in Regeneron, there are other reasons to consider buying the stock. I think you said recently, Brian, that they just don't fail. [laughs] Has Regeneron had any failures? [laughs] Not recently.</p><p><b>Orelli:</b> Not late-stage failure certainly. I can't think of any failures that they've had.</p><p><b>Speights:</b> The company has several drugs with fast-growing sales. This is obviously promising news with this antibody therapy. But like you say, Brian, it remains to be seen whether or not it's going to have market traction over the long run. It's hard to say. It's hard to say what's going to happen in the world of COVID-19 beyond the pandemic.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Will Regeneron's COVID Cocktail Win Be Short-Lived?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWill Regeneron's COVID Cocktail Win Be Short-Lived?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-21 18:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/21/will-regenerons-covid-cocktail-win-be-short-lived/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Regeneron Pharmaceuticals (NASDAQ:REGN) recently racked up a couple of additional successes with late-stage studies of its COVID-19 antibody cocktail REGEN-COV. In this Motley Fool Live video recorded...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/21/will-regenerons-covid-cocktail-win-be-short-lived/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司"},"source_url":"https://www.fool.com/investing/2021/04/21/will-regenerons-covid-cocktail-win-be-short-lived/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2129875413","content_text":"Regeneron Pharmaceuticals (NASDAQ:REGN) recently racked up a couple of additional successes with late-stage studies of its COVID-19 antibody cocktail REGEN-COV. In this Motley Fool Live video recorded on April 14, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether the biotech's COVID cocktail win will only be short-lived.Keith Speights: Regeneron Pharmaceuticals, the ticker there is REGN, had two positive announcements for its COVID-19 antibody cocktail, REGEN-COV. They announced both of these new developments on Monday.The company reported results from a late-stage study that showed that this antibody cocktail significantly reduced progression to symptomatic COVID-19 in patients who had been recently infected. It also announced results from another phase 3 study that showed the antibody cocktail reduced the risk of infection for individuals in households where another person had been infected by the coronavirus.These are definitely positive stories for Regeneron, but do you think these wins will translate to significant revenue for the biotech? Or could these wins actually be short-lived?Brian Orelli: Obviously as more and more people get vaccinated the infection rates should go down, and then therefore the opportunity to treat people either prophylactically because they've been exposed or because they realized that they test positive but don't have any symptoms and then want this antibody cocktail, that opportunity is going to be go down, but it's not going to go to zero, and so I think there's an opportunity for some treatments.But certainly the market for treatments is going to diminish substantially over the next few months and into the next year. I don't know.The other wildcard here is the variance. The variance pop up and we can't keep up fast enough with them, and they are infecting enough people that are already vaccinated and we can't keep up creating new vaccine fast enough, then I think that's another opportunity for the treatments that they don't have right now.Speights: I think that's a really good take on it, Brian. If you're looking at potentially investing in Regeneron, there are other reasons to consider buying the stock. I think you said recently, Brian, that they just don't fail. [laughs] Has Regeneron had any failures? [laughs] Not recently.Orelli: Not late-stage failure certainly. I can't think of any failures that they've had.Speights: The company has several drugs with fast-growing sales. This is obviously promising news with this antibody therapy. But like you say, Brian, it remains to be seen whether or not it's going to have market traction over the long run. It's hard to say. It's hard to say what's going to happen in the world of COVID-19 beyond the pandemic.","news_type":1},"isVote":1,"tweetType":1,"viewCount":486,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}